Piramal Enterprises Limited (PEL) is one of India’s leading diversified companies, with a presence in Financial Services and Pharmaceuticals. PEL’s consolidated revenues were ~US$1.7 Billion in FY2020, with around ~34% of revenues generated from outside India. Driven by both organic as well as inorganic strategy, PEL has steered dynamic business growth over the three decades of its existence.
Anticipating the potential of financial services in India, PEL built a platform with innovative financial solutions that cater to the needs of varied industry verticals.
It made its foray into the financial services sector with Piramal Capital & Housing Finance Limited (PCHFL), a housing finance company registered with the National Housing Bank (NHB) that is engaged in various financial services businesses. It provides end-to-end financing solutions in both wholesale and retail funding opportunities across sectors such as real estate and infrastructure, renewable energy, hospitality, logistics, industrials, auto components etc.
Utilizing its strong domestic presence, network as well as investing track record, Piramal Alternatives was set-up as the Group’s fiduciary third-party capital management business investing across the capital structure across equity as well as debt with leading global institutional investors such as Caisse de dépôt et placement du Québec (CDPQ), Bain Capital Credit, Canadian Pension Plan Investment Board (CPPIB) and APG as partners. As the Indian economy evolves, Piramal Alternatives looks to be a significant provider of customized financing solutions to high-quality corporates that are looking to maximize their growth.
When the Indian pharmaceutical industry was focused on international generics, PEL saw an opportunity to expand its pharma business and invested in the domestic formulation business.
Piramal Pharma Limited (PPL), a subsidiary of PEL, offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 14 global facilities and a global distribution network in over 100 countries. PPL includes: Pharma Solutions, an integrated contract development and manufacturing (CDMO) business; Critical Care, a complex hospital generics business and the Consumer Healthcare business, selling over-the-counter products in India. It also has a joint venture with Allergan, a leader in ophthalmology in the Indian formulations market.
PEL’s corporate ethos, a reflection of its core values – Knowledge, Action, Care and Impact, has enabled the company to develop and consolidate a coveted international business network of strong partnerships with global market leaders, committed to creating long-term value to all stakeholders.
Operational excellence fuelled by continued innovation
Delivering sustained long-term value to all stakeholders
Fostering an environment of entrepreneurship